318: Drug pricing drops & psychedelics under fire

Rachel Cohrs Zhang, chief Washington correspondent for STAT, talks about the recent pharmaceutical negotiations with Medicare, highlighting significant discounts and the industry's reactions. Meghana Keshavan dives into the world of psychedelics, discussing the troubling retraction of three pivotal research papers and FDA setbacks for notable therapies. They explore the ethical implications of these developments and the future of psychedelic treatments in mental health, emphasizing the implications for regulatory integrity and research credibility.